Matthew Hoffmann currently serves as Senior Director of DMPK at Insmed Incorporated, a position held since June 2023. Prior experience includes roles as Senior Director of DMPK at Bristol-Myers Squibb from November 2019 to June 2023, and as Director of DMPK at Celgene from May 2009 to November 2019. Matthew began a career in drug metabolism at Wyeth Research as Section Head from October 2000 to May 2009, leading a drug metabolism and biotransformation laboratory while collaborating with interdisciplinary teams on drug candidate development. Matthew holds a PhD in Toxicology and Drug Metabolism from Rutgers University and a BS in Biology from Cornell University.
This person is not in any teams
This person is not in any offices